Bristol-Myers Squibb (NYSE:BMY) isn’t having a great year. The big pharma stock has spent most of 2019 in negative territory. Many investors weren’t happy with the decision to acquire Celgene (NASDAQ:CELG). And BMS has experienced some clinical-study disappointments for its blockbuster cancer drug, Opdivo. But is Bristol-Myers Squibb still a smart pick for long-term investors?Continue Reading